Veterinary Compounding

Size: px
Start display at page:

Download "Veterinary Compounding"

Transcription

1 Veterinary Compounding Veterinarians occasionally use compounded preparations to meet a specific patient s medical need. The purpose of this brochure, created jointly by the Animal Health Institute (AHI), the American Veterinary Distributors Association (AVDA), and the American Veterinary Medical Association (AVMA), is to explain the Food and Drug Administration (FDA) requirements for compounding preparations for veterinary use and the distinction between drug products approved by the US FDA and compounded preparations. 1

2 Table of Contents Federal Regulations to Follow... 1 Compounding from Unapproved Substances... 2 Compounded Preparations Are Not Generic Drug Products... 3 How to Identify an FDA-Approved Animal Drug Product... 3 Inappropriate Compounding Pharmacy Practices... 4 Questions to Ask Your Pharmacist Cha racteristics of FDA-Approved Products vs. Compounded Preparations Additional Resources...Back Cover What is compounding? Compounding that is consistent with the FDA Extra-Label Drug Use regulations is the customized manipulation of an approved drug(s) by a veterinarian, or by a pharmacist upon the prescription of a veterinarian, to meet the needs of a particular patient. For example, mixing two injectable drugs is compounding. Preparing a paste or suspension from crushed tablets is another example of compounding. Likewise, adding flavoring to a drug is compounding. Be aware, however, that products are being promoted to veterinarians under the guise of compounding that do not fit this definition. According to the FDA, legal compounding is not the formulation of preparations from bulk or raw active ingredients. Compounding should not be used as a way of circumventing the drug approval process or producing a product so it can be sold for less cost than an FDA-approved drug.

3 Federal Regulations to Follow The FDA regulations and Compliance Policy Guide Compounding of Drugs for Use in Animals describe specific circumstances under which FDA will either permit compounding for use in animals or may exercise its enforcement discretion: A valid Veterinarian-Client-Patient relationship exists. The health of an animal is threatened, or suffering or death may result from failure to treat. Compounding is performed by a licensed veterinarian or a licensed pharmacist on the order of a veterinarian within the scope of professional practice. There is no approved animal or human drug that, when used as labeled or in conformity with the extralabel drug use regulations, will, in the available dosage form and concentration, appropriately treat the condition diagnosed. Preparations are compounded from FDA-approved animal or human drugs. Nothing in the regulations permits compounding from bulk (raw pharmaceutical ingredient) drugs. Compounding from a human drug for use in food-producing animals is not permitted if an approved animal drug can be used for the compounding. For animals produced for human consumption, the veterinarian institutes procedures to assure the identity of treated animals, establishes a substantially extended withdrawal interval for the compounded preparation supported by appropriate scientific information, and ensures food safety. Compounding is not permitted if it results in violative food residue or any residue that may present a risk to public health. No drug may be compounded for food animals from drugs listed on the prohibited list (go to and enter in the search engine). Veterinarians comply with all aspects of the federal extralabel drug use regulations including record-keeping and labeling requirements. Adequate procedures and processes are followed that ensure the safety and effectiveness of the compounded product. The scale of compounding in advance of receiving prescriptions is limited and commensurate with the established need for compounded products. All relevant state laws relating to the compounding of drugs for use in animals are followed. 1

4 Compounding from Unapproved Substances Federal regulations describe specific circumstances under which veterinarians, or pharmacists upon veterinarians prescriptions, are legally permitted to compound drugs for extralabel use in animals. Under these regulations, compounding for non-food animals may only be performed using FDA-approved animal or human drug products and only when there is no approved animal or human drug product available in the relevant dosage form and concentration to appropriately treat the diagnosed condition. Compounding from human drugs for use in food animals is not allowed if an approved animal drug can be utilized. However, veterinarians may occasionally face situations where they diagnose conditions for which no FDA-approved product is available for use to relieve the animal s suffering or prevent the animal s death. The current state of veterinary medicine requires products to treat many conditions in a number of different species, some of which are known to have unique physiological characteristics. Although FDA considers it a violation of the Federal Food, Drug and Cosmetic Act, it acknowledges the need for compounding from bulk active or raw ingredients within certain areas of veterinary practice. For example, the FDA published a list of bulk drug substances for compounding and subsequent use in animals to which FDA would exercise enforcement discretion and not ordinarily object, specifically poison antidotes available only as bulk chemicals. In these situations or others, veterinarians may find it necessary to compound, or prescribe for a pharmacist to compound, from the bulk chemical to satisfy the requirements of good veterinary medical practice. The veterinarian and/or pharmacist are then responsible for the safety and efficacy of the compounded drug. In cases where no approved drug or combination of approved drugs can adequately address a specific patient s need, veterinarians and pharmacists must carefully assess whether the use of an unapproved substance in a compounded veterinary drug is consistent with state and federal law and FDA policy. 2

5 Compounded Preparations are not Generic Drug Products Generic drug products are very different from compounded preparations. Generic drug products are FDA-approved, which requires a demonstration of bioequivalence of safety and efficacy with the pioneer drug product. Generic animal drug products are identified by an Abbreviated New Animal Drug Application (ANADA) number on their label or in FDA drug references. In contrast to generic drugs, compounded preparations lack FDA approval. How to Identify an FDA-Approved Animal Drug Product FDA-approved animal drug products can be identified by the six-digit New Animal Drug Application (NADA) number for brand-name drug products or the six-digit ANADA number for generic drug products. The NADA or ANADA number and the statement Approved by FDA can usually be found on the drug product s label including the package insert. It may also be helpful to cross-check with a drug reference, such as the FDA s online databases, Animal FDA and FDA Orange Book, which list approved animal and human drug products, respectively. The presence of a National Drug Code (NDC) number on a product label does not confer FDA approval. 3

6 Inappropriate Compounding Pharmacy Practices Include the Following: Compounded preparations that mimic FDA-approved drug products. Beware of pharmacies that purport to sell compounded preparations that are the same as commercially available FDA-approved products or similar but with a minor difference, such as a slightly different concentration. Often these are marketed as a cheaper alternative to the approved drug. FDA has not identified price as a legitimate reason for prescribing a compounded preparation. Legitimate compounding is prescription-driven and predicated upon the need to customize a preparation to meet an individual patient s needs. Manufacturing under the guise of compounding. The use of commercial scale equipment and preparation of large quantities of compounded products in anticipation of receiving orders. Promotion and advertising of unapproved new animal drugs. FDA considers products compounded from bulk active ingredients to be unapproved new animal drugs. Wholesale distribution of compounded preparations. It is not legal for compounded preparations to be developed in large quantities and sold to third parties (including veterinarians and companies) or wholesalers, to resell to individual patients. 4

7 Questions To Ask Your Pharmacist Q: What are your credentials for preparing compounds for use in animals? A: Pharmacy undergraduate education offers varying degrees of compounding instruction, and training in veterinary pharmacotherapy may be limited. Postgraduate pharmacy training can include continuing education certificates and membership in veterinary pharmacy professional organizations. Consider whether the pharmacy is compliant with United States Pharmacopeia (USP) standards, such as General Chapters <795> and <797> for non-sterile and sterile compounding for both humans and animals. Q: Are you licensed as a pharmacy in my state? Is the pharmacy accredited by an independent body? A: Most state boards of pharmacy require that an out-of-state pharmacy register with their state prior to filling prescriptions to be mailed into their state. Veterinarians can inquire with their state board of pharmacy to ascertain the status of a pharmacy s license and to gain valuable information including the pharmacy permit number. Also, consider whether the pharmacy is certified by an independent body. Examples include the National Association of Boards of Pharmacy s Vet-VIPPS and the Pharmacy Compounding Accreditation Board. Q: What sources will you use for the components and formula for the compound I am prescribing? A: FDA-approved products should be used to make compounded preparations. In cases where no approved drug or combination of approved drugs can adequately address a specific patient s need, veterinarians and pharmacists must carefully assess whether the use of an unapproved substance in a compounded veterinary drug is consistent with state and federal law and FDA policy. If medical necessity dictates that a bulk active ingredient be used in the formulation, the pharmacist should ensure the integrity of all components used (e.g. certificates of analysis, USP National Formulary grade substance, or substances obtained from an FDA-registered supplier.) The pharmacist can also identify the company from which products are purchased as well as the domestic or international location of the company. Formulas used for compounding should be obtained from a peer-reviewed source (e.g. published studies in primary literature, textbooks, or the USP) when possible. 5

8 Questions To Ask Your Pharmacist Q: What assurances can be offered regarding the quality and stability of the preparation? A: There are both benefits and risks associated with compounded preparations used in animals. While they may be useful when medically necessary, the reality is that no assurances can be given without sufficient scientific data backing the preparation method of each active ingredient. However, some assurances of the quality of active ingredients and preparation methods can be offered by the pharmacy to help mitigate certain risks that are also associated with compounding, such as poor quality ingredients or unstable preparations. Q: How do I know that the compounded preparations such as drug delivery systems or drug combinations will be safe and effective? A: You don t. There is no assurance, like there is with an FDA-approved drug, that a compounded preparation will be safe or effective for the condition you are treating. Extensive laboratory and clinical studies are needed to assure that these preparations achieve adequate blood and tissue levels on a consistent basis from batch to batch as well as being safe to the animal. Sponsors of FDA approved products must conduct in vivo pre-market testing. Veterinarians should seek results from scientifically designed studies demonstrating the efficacy and safety of a particular preparation, including drug delivery systems in the target species. These study results showing suitable stability, relative efficacy, and safety in the target species can be considered in the benefit-risk analysis a veterinarian performs when deciding whether to use the particular preparation in the patient. Q: What data or other sources will you use for the assigned beyond-use date for the compound I am prescribing? A: Veterinarians should inquire as to how the beyond-use date was established. Beyond-use dates and expiration dates are not the same. Expiration dates for the chemical and physical stability of manufactured products are determined from results of rigorous analytical and performance testing, and they are specific for a particular formulation in its container and at stated exposure conditions. According to the USP (e.g. General Chapters <795> and <797>), the compounding pharmacist is responsible for setting the beyond-use date within the conservative default parameters established by USP. 6

9 Q: Will you prepare a compound specifically for my patient, or is it prepared in advance? A: Pharmacies should compound medications pursuant to the receipt of a valid prescription. Q: How would I report an adverse event that I think is associated with use of a compounded preparation? A: Veterinarians should report suspected adverse events or product failures involving compounded preparations to the compounding pharmacist, the state board of pharmacy, and the FDA Center for Veterinary Medicine. Instructions for reporting adverse events to FDA can be found at the FDA website AnimalVeterinary/SafetyHealth/ReportaProblem/ucm htm. Pharmacists should instruct pet owners to contact both the prescribing veterinarian and pharmacist immediately if a compounded preparation has caused an adverse event. 1 The information in this brochure should not be construed as legal advice or legal opinion on specific facts, and is not intended as a definitive statement on the subject of compounding preparations for veterinary use. Rather, this brochure is intended to serve as a tool for veterinarians and other readers, providing practical information on the subject of veterinary compounding. 7

10 Characteristics of FDA-Approved Products vs. Compounded Preparations CHARACTERISTICS BENEFIT FDA APPROVED DRUG PRODUCT: NEW ANIMAL DRUG (NADA)/ GENERIC ANIMAL DRUG (ANADA) COMPOUNDED DRUG FDA approval Agency substantiation of manufacturers drug label claims that are supported with substantial scientific evidence and language that are sufficiently clear to ensure safe and effective use of the product. NO Tested in labeled animal species in laboratory and field trials Drug s safety and efficacy must be scientifically demonstrated NO Manufactured according to current Good Manufacturing Practices (cgmps) Ensures each batch is manufactured within specification for therapeutic consistency NO Manufacturing facilities inspected and approved by FDA Ensures manufacturer compliance with FDA regulations governing product quality NO Ongoing stability testing of drugs Ensures drug shelf life matches labeled expiration date NO 8

11 CHARACTERISTICS BENEFIT FDA APPROVED DRUG PRODUCT: NEW ANIMAL DRUG (NADA)/ GENERIC ANIMAL DRUG (ANADA) COMPOUNDED DRUG Prescription drug advertising and promotional material submitted to and reviewed by FDA Means nothing is false or misleading about the materials NO Adverse events or lack of efficacy reported to FDA Permits unanticipated yet significant post-marketing experiences to be communicated back from FDA to the veterinarian Analytical testing of product prior to release for Strength Identity Purity Ensures that product contains what is represented on the label Unknown Unknown Unknown 9

12 Resources FDA Center for Veterinary Medicine FDA Extralabel Drug Use Rules (21 CFR 530.3, , ) CPG Sec Compounding of Drugs for Use in Animals Animal FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations United States Pharmacopeia National Formulary (USP-NF) Papich, MG. Drug Compounding for Veterinary Patients. AAPS J 2005; 07(02):E281-E287 National Association of Boards of Pharmacy American Veterinary Medical Association American Association of Bovine Practitioners American Association of Equine Practitioners Pharmacy Compounding Accreditation Board American Association of Feline Practitioners This document was prepared by the Animal Health Institute (AHI), the American Veterinary Medical Association (AVMA), and the American Veterinary Distributors Association (AVDA). For additional copies of this brochure, contact AVDA headquarters at or avda@ksgroup.org.

Minnesota Board of Pharmacy. Guidance on the Compounding of Veterinary Products Approved: March 4, 2015

Minnesota Board of Pharmacy. Guidance on the Compounding of Veterinary Products Approved: March 4, 2015 EXECUTIVE SUMMARY Minnesota Board of Pharmacy Guidance on the Compounding of Veterinary Products Approved: March 4, 2015 Board staff has held several meetings with representatives of the Minnesota Veterinary

More information

PRINCIPLES OF VETERINARY MEDICAL ETHICS OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION (AVMA)

PRINCIPLES OF VETERINARY MEDICAL ETHICS OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION (AVMA) PRINCIPLES OF VETERINARY MEDICAL ETHICS OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION (AVMA) (Bold print states the Principles, standard print explains or clarifies the Principle to which it applies)

More information

The following Good Compounding Practices (GCPs) are meant to apply only to the compounding of drugs by State-licensed pharmacies.

The following Good Compounding Practices (GCPs) are meant to apply only to the compounding of drugs by State-licensed pharmacies. 1 NABP Model State Pharmacy Act & Model Rules Appendix B Good Compounding Practices Applicable to State Licensed Pharmacies The following Good Compounding Practices (GCPs) are meant to apply only to the

More information

IACP Comparison of 503A and 503B The Drug Quality and Security Act of 2013

IACP Comparison of 503A and 503B The Drug Quality and Security Act of 2013 Exempt Sections within the Food, Drug, and Cosmetic Act If a "traditional compounder", defined as a licensed pharmacist or licensed physician, meets ALL conditions within Section 503A, the compounder is

More information

Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs

Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction

More information

2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC

2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC 2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC Objectives 1. Review the changes to the pharmacy practice act related to sterile compounding. 2. Understand the role of the

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Jabones Pardo S.A.

More information

247 CMR: BOARD OF REGISTRATION IN PHARMACY

247 CMR: BOARD OF REGISTRATION IN PHARMACY 247 CMR 9.00: CODE OF PROFESSIONAL CONDUCT; PROFESSIONAL STANDARDS FOR REGISTERED PHARMACISTS, PHARMACIES AND PHARMACY DEPART- MENTS Section 9.01: Code of Professional Conduct for Registered Pharmacists,

More information

Guidance for Industry Time and Extent Applications for Nonprescription Drug Products

Guidance for Industry Time and Extent Applications for Nonprescription Drug Products Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

I. Objectives. Justification for clinical education

I. Objectives. Justification for clinical education NC STATE UNIVERSITY RESIDENCY PROGRAM IN VETERINARY CLINICAL PHARMACY The College of Veterinary Medicine, North Carolina State University, is offering a residency program in Veterinary Clinical Pharmacy

More information

Legal and Ethical Veterinary Compounding. Scott D. Stanley, Ph.D., Professor University of California, Davis School of Veterinary Medicine

Legal and Ethical Veterinary Compounding. Scott D. Stanley, Ph.D., Professor University of California, Davis School of Veterinary Medicine Legal and Ethical Veterinary Compounding Scott D. Stanley, Ph.D., Professor University of California, Davis School of Veterinary Medicine American Association of Equine Practitioners 2009 Equine Chemistry

More information

Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice

Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Kurt R. Karst Hyman, Phelps & McNamara, P.C. 700 Thirteenth Street, N.W., Suite 1200 Washington, D.C.

More information

DRUG COMPOUNDING FOR ANIMALS. FDA Could Improve Oversight with Better Information and Guidance

DRUG COMPOUNDING FOR ANIMALS. FDA Could Improve Oversight with Better Information and Guidance United States Government Accountability Office Report to Congressional Committees September 2015 DRUG COMPOUNDING FOR ANIMALS FDA Could Improve Oversight with Better Information and Guidance GAO-15-671

More information

Principles of Good Practice for Advertising and Promotion of Animal Health Products. A Voluntary Guideline Developed by the Animal Health Institute

Principles of Good Practice for Advertising and Promotion of Animal Health Products. A Voluntary Guideline Developed by the Animal Health Institute Principles of Good Practice for Advertising and Promotion of Animal Health Products A Voluntary Guideline Developed by the Animal Health Institute The Animal Health Institute is the U.S. trade association

More information

H4235 An Act relative to pharmacy practice in the Commonwealth

H4235 An Act relative to pharmacy practice in the Commonwealth H4235 An Act relative to pharmacy practice in the Commonwealth Summary THE BOARD OF REGISTRATION IN PHARMACY SECTIONS 2 & 3. The Board of Registration in Pharmacy is expanded to include 13 individuals,

More information

Extemporaneously Prepared Early Phase Clinical Trial Materials

Extemporaneously Prepared Early Phase Clinical Trial Materials Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development

More information

Annex 7 Guidelines on pre-approval inspections

Annex 7 Guidelines on pre-approval inspections World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the

More information

2014 Annual Report on Inspections of Establishments

2014 Annual Report on Inspections of Establishments 2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered

More information

Investigational Drugs: Investigational Drugs and Biologics

Investigational Drugs: Investigational Drugs and Biologics : I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place

More information

Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation

Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle

FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle Kurt R. Karst Associate Hyman, Phelps & McNamara, P.C. 700 Thirteenth

More information

Health Canada Manufacturing and Compounding Drug Products in Canada: A Policy Framework Guidelines for P.E.I. Community and Hospital Pharmacists

Health Canada Manufacturing and Compounding Drug Products in Canada: A Policy Framework Guidelines for P.E.I. Community and Hospital Pharmacists Health Canada Manufacturing and Compounding Drug Products in Canada: A Policy Framework Guidelines for P.E.I. Community and Hospital Pharmacists October 2001 In response to pharmacists questions about

More information

(1) Cancer drug means a prescription drug that is used to treat cancer or the side effects of cancer.

(1) Cancer drug means a prescription drug that is used to treat cancer or the side effects of cancer. DEPARTMENT OF PUBLIC HEALTH AND ENVIRONMENT Health Promotion and Disease Prevention Services CANCER DRUG REPOSITORY PROGRAM 6 CCR 1015-10 [Editor s Notes follow the text of the rules at the end of this

More information

Pre-Approval Process INAD vs. NADA

Pre-Approval Process INAD vs. NADA Pre-Approval Process INAD vs. NADA Barbara M. Leotta, DVM CVM/ONADE/DTDNFA (240)276-8262 barbara.leotta@fda.hhs.gov Pre-Approval Process General Overview Pathways To Legal Marketing Office of New Animal

More information

Disclaimer: The following transcript is a draft and is pending review for accuracy by the speakers. Edits have been made for clarity.

Disclaimer: The following transcript is a draft and is pending review for accuracy by the speakers. Edits have been made for clarity. Want to comment? Your input is important. OLAW welcomes questions and comments from viewers of this recording. OLAW will post the comments, questions, and answers on the OLAW website. Please go to the

More information

THE DRUGS AND COSMETICS RULES, 1945

THE DRUGS AND COSMETICS RULES, 1945 THE DRUGS AND COSMETICS RULES, 1945 PART VI SALE OF DRUGS OTHER THAN HOMOEOPATHIC MEDICINES 59. (1) The State Government shall appoint Licensing Authorities for the purpose of this Part for such areas

More information

Pre-market Information - Class III and IV

Pre-market Information - Class III and IV Pre-market Information - Class III and IV Life Sciences Council British Columbia NRC Industry Research Assistance Program Vancouver, October 29, 2007 Mary-Jane Bell, Ph.D. Medical Devices Bureau (MDB)

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Providing Regulatory Submissions in Electronic Format Drug Establishment Registration and Drug Listing U.S. Department of Health and Human Services Food and Drug Administration Office

More information

Standards of Practice for Pharmacists and Pharmacy Technicians

Standards of Practice for Pharmacists and Pharmacy Technicians Standards of Practice for Pharmacists and Pharmacy Technicians Introduction These standards are made under the authority of Section 133 of the Health Professions Act. They are one component of the law

More information

REGULATION 3 PHARMACY TECHNICIANS

REGULATION 3 PHARMACY TECHNICIANS REGULATION 3 PHARMACY TECHNICIANS 03-00 PHARMACY TECHNICIANS REGISTRATION/PERMIT REQUIRED 03-00-0001 DEFINITIONS (a) Pharmacy technician means those individuals, exclusive of pharmacy interns, who assist

More information

CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE)

CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE) CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE) Section 61-03-02-01 Definitions 61-03-02-02 Absence of Provider or Consulting Pharmacist

More information

Enrolled Copy S.B. 55

Enrolled Copy S.B. 55 Enrolled Copy S.B. 55 1 PHARMACEUTICAL DISPENSING AMENDMENTS 2 2014 GENERAL SESSION 3 STATE OF UTAH 4 Chief Sponsor: Evan J. Vickers 5 House Sponsor: Stewart Barlow 6 Cosponsors: Brian E. Shiozawa 7 Curtis

More information

8. A listing of the medications that are approved for use within a system is a/an A) inventory. B) wholesaler. C) database. D) formulary.

8. A listing of the medications that are approved for use within a system is a/an A) inventory. B) wholesaler. C) database. D) formulary. Name: Date: 1. A pharmacy technician searching for standards of practice regarding compounding sterile and non-sterile products would consult which reference book? A) King's Guide to Parenteral Admixtures

More information

1083.4 SUPPLY CHAIN INTEGRITY AND SECURITY

1083.4 SUPPLY CHAIN INTEGRITY AND SECURITY BRIEFING 1083.4 Supply Chain Integrity and Security. A new series of general informational chapters describing various aspects of the pharmaceutical supply chain replaces Good Distribution Practices Supply

More information

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics

More information

Guidance for Industry

Guidance for Industry Guidance for Industry FDA Export Certificates Submit comments and suggestions regarding this document at anytime to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane,

More information

Guidance for Industry Consumer-Directed Broadcast Advertisements

Guidance for Industry Consumer-Directed Broadcast Advertisements Guidance for Industry Consumer-Directed Broadcast Advertisements U.S. Department of Health and Human Services Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research

More information

Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP

Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP Document issued on: June 2004 U.S. Department of Health and Human Services Food and Drug Administration

More information

CHAPTER 6 PROCUREMENT AND SUPPLY OF PHARMACEUTICAL PRODUCTS IN THE PUBLIC AND PRIVATE MEDICAL SECTORS

CHAPTER 6 PROCUREMENT AND SUPPLY OF PHARMACEUTICAL PRODUCTS IN THE PUBLIC AND PRIVATE MEDICAL SECTORS CHAPTER 6 PROCUREMENT AND SUPPLY OF PHARMACEUTICAL PRODUCTS IN THE PUBLIC AND PRIVATE MEDICAL SECTORS Overview 6.1 This chapter sets out the Review Committee s findings and recommendations on procurement

More information

03 PHARMACY TECHNICIANS

03 PHARMACY TECHNICIANS 03 PHARMACY TECHNICIANS 03-00 PHARMACY TECHNICIANS REGISTRATION/PERMIT REQUIRED 03-00-0001 DEFINITIONS: A. PHARMACY TECHNICIAN: This term refers to those individuals identified as Pharmacist Assistants

More information

RULES PERTAINING TO THE PRACTICE OF VETERINARY MEDICINE TEXAS ADMINISTRATIVE CODE TITLE 22, PART 24 CHAPTER 573

RULES PERTAINING TO THE PRACTICE OF VETERINARY MEDICINE TEXAS ADMINISTRATIVE CODE TITLE 22, PART 24 CHAPTER 573 RULES PERTAINING TO THE PRACTICE OF VETERINARY MEDICINE TEXAS ADMINISTRATIVE CODE TITLE 22, PART 24 CHAPTER 573 TEXAS BOARD OF VETERINARY MEDICAL EXAMINERS 333 Guadalupe, Ste. 3-810 Austin, TX 78701-3942

More information

PHARMACEUTICAL MANAGEMENT PROCEDURES

PHARMACEUTICAL MANAGEMENT PROCEDURES PHARMACEUTICAL MANAGEMENT PROCEDURES THE FORMULARY The purpose of Coventry Health Care s formulary is to encourage use of the most cost-effective drugs. The formulary is necessary because the cost of prescription

More information

Health Products and Food Branch. www.hc-sc.gc.ca

Health Products and Food Branch. www.hc-sc.gc.ca Health Products and Food Branch 1 HEALTH CANADA PART C DIVISION 5 - DRUGS FOR CLINICAL TRIALS INVOLVING HUMAN SUBJECTS Part C - Division 5 2 Part A: Part B: Part C: Part D: Part E: Part G: Part J: Administration

More information

House Study Bill 503 - Introduced

House Study Bill 503 - Introduced House Study Bill 0 - Introduced HOUSE FILE BY (PROPOSED COMMITTEE ON HUMAN RESOURCES BILL BY CHAIRPERSON MILLER) A BILL FOR An Act relating to prescription authority for certain psychologists and making

More information

SECTION.1800 - PRESCRIPTIONS

SECTION.1800 - PRESCRIPTIONS SECTION.1800 - PRESCRIPTIONS 21 NCAC 46.1801 EXERCISE OF PROFESSIONAL JUDGMENT IN FILLING PRESCRIPTIONS (a) A pharmacist or device and medical equipment dispenser shall have a right to refuse to fill or

More information

Overview of Pre-Approval Inspections

Overview of Pre-Approval Inspections Overview of Pre-Approval Inspections Presented by: Kelli F. Dobilas NWJ-DO Pre-Approval Manager Pre-Approval Drug Inspections What are Pre-Approval Inspections? One of the last reviews of the drug approval

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2006 Compliance

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2006 Compliance Guidance for Industry Prescription Drug Marketing Act Donation of Prescription Drug Samples to Free Clinics U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

ENROLLED SENATE BILL No. 92

ENROLLED SENATE BILL No. 92 Act No. 285 Public Acts of 2014 Approved by the Governor September 23, 2014 Filed with the Secretary of State September 23, 2014 EFFECTIVE DATE: December 22, 2014 STATE OF MICHIGAN 97TH LEGISLATURE REGULAR

More information

Exceptions to the Rule: A Pharmacy Law Presentation. Objectives DISCLAIMER 10/16/2015

Exceptions to the Rule: A Pharmacy Law Presentation. Objectives DISCLAIMER 10/16/2015 Exceptions to the Rule: A Pharmacy Law Presentation Eric Roath, Pharm.D. Director of Professional Practice Michigan Pharmacists Association Objectives 1. Identify basic legal frameworks that govern the

More information

Louisiana Administrative Code. Title 46 Professional and Occupational Standards. Part LIII: Pharmacists

Louisiana Administrative Code. Title 46 Professional and Occupational Standards. Part LIII: Pharmacists Chapter 17. Institutional Pharmacy Louisiana Administrative Code Title 46 Professional and Occupational Standards Subchapter A. General Requirements Part LIII: Pharmacists 1701. Cross References A. For

More information

ALABAMA BOARD OF NURSING ADMINISTRATIVE CODE CHAPTER 610-X-5 ADVANCED PRACTICE NURSING COLLABORATIVE PRACTICE TABLE OF CONTENTS

ALABAMA BOARD OF NURSING ADMINISTRATIVE CODE CHAPTER 610-X-5 ADVANCED PRACTICE NURSING COLLABORATIVE PRACTICE TABLE OF CONTENTS ALABAMA BOARD OF NURSING ADMINISTRATIVE CODE CHAPTER 610-X-5 ADVANCED PRACTICE NURSING COLLABORATIVE PRACTICE TABLE OF CONTENTS 610-X-5-.01 610-X-5-.02 610-X-5-.03 610-X-5-.04 610-X-5-.05 610-X-5-.06 610-X-5-.07

More information

New Law Extends Federal Oversight of Compounding Pharmacies, Establishes National Drug Track-and-Trace Requirements

New Law Extends Federal Oversight of Compounding Pharmacies, Establishes National Drug Track-and-Trace Requirements New Law Extends Federal Oversight of Compounding Pharmacies, Establishes National Drug Track-and-Trace Requirements January 22, 2014 Boston Brussels Chicago Düsseldorf Frankfurt Houston London Los Angeles

More information

Health Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents

Health Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents Health Professions Act BYLAWS SCHEDULE F PART 2 Hospital Pharmacy Standards of Practice Table of Contents 1. Application 2. Definitions 3. Drug Distribution 4. Drug Label 5. Returned Drugs 6. Drug Transfer

More information

LAW ON MEDICINES. Article 1. Article 2. Article 3 Manufacturing and marketing of medical devices is the activity of public interest.

LAW ON MEDICINES. Article 1. Article 2. Article 3 Manufacturing and marketing of medical devices is the activity of public interest. LAW ON MEDICINES I BASIC PROVISIONS Article 1 This Law regulates conditions for manufacturing and marketing medicines for human use and use in veterinary medicine, measures for quality assurance, safety

More information

Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion

Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS Eli Lilly & Co. Principal Consultant - Regulatory PDA/FDA Joint September 20 th, 2011

More information

GUIDELINES ON COMPOUNDING OF MEDICINES. March 2015. PharmBA1502 01

GUIDELINES ON COMPOUNDING OF MEDICINES. March 2015. PharmBA1502 01 GUIDELINES ON COMPOUNDING OF MEDICINES March 2015 PharmBA1502 01 Contents Who needs to use these guidelines?............................................. 3 Introduction..........................................................

More information

Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs

Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session 6: WHO Prequalification Programme Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session adapted from the WHO training workshop on prequalification and the WHO technical briefing seminar

More information

Importing pharmaceutical products to China

Importing pharmaceutical products to China Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval

More information

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications DRAFT GUIDANCE This guidance document is being distributed

More information

07 LC 33 1788 A BILL TO BE ENTITLED AN ACT BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

07 LC 33 1788 A BILL TO BE ENTITLED AN ACT BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA: 0 LC House Bill 0 By: Representative Stephens of the th A BILL TO BE ENTITLED AN ACT To amend Chapter of Title of the Official Code of Georgia Annotated, relating to pharmacists and pharmacies, so as to

More information

STATE OF MAINE IN THE YEAR OF OUR LORD TWO THOUSAND AND FIFTEEN S.P. 288 - L.D. 814. An Act To Update the Maine Veterinary Practice Act

STATE OF MAINE IN THE YEAR OF OUR LORD TWO THOUSAND AND FIFTEEN S.P. 288 - L.D. 814. An Act To Update the Maine Veterinary Practice Act CHAPTER GOVERNOR'S VETO OVERRIDDEN 209 JUNE 16, 2015 PUBLIC LAW STATE OF MAINE IN THE YEAR OF OUR LORD TWO THOUSAND AND FIFTEEN S.P. 288 - L.D. 814 An Act To Update the Maine Veterinary Practice Act Be

More information

ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE CHAPTER 540-X-8 ADVANCED PRACTICE NURSES: COLLABORATIVE PRACTICE TABLE OF CONTENTS

ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE CHAPTER 540-X-8 ADVANCED PRACTICE NURSES: COLLABORATIVE PRACTICE TABLE OF CONTENTS Medical Examiners Chapter 540-X-8 ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE CHAPTER 540-X-8 ADVANCED PRACTICE NURSES: COLLABORATIVE PRACTICE TABLE OF CONTENTS 540-X-8-.01 540-X-8-.02 540-X-8-.03

More information

Division of Professional Licensure Massachusetts Board of Registration in Pharmacy 239 Causeway Street, Fifth Floor Boston, Massachusetts 02114

Division of Professional Licensure Massachusetts Board of Registration in Pharmacy 239 Causeway Street, Fifth Floor Boston, Massachusetts 02114 Division of Professional Licensure Massachusetts Board of Registration in Pharmacy 239 Causeway Street, Fifth Floor Boston, Massachusetts 02114 (617) 727-0085 www.state.ma.us/reg/boards/ph CONTENTS Page

More information

Draft guidance for registered pharmacies preparing unlicensed medicines

Draft guidance for registered pharmacies preparing unlicensed medicines Draft guidance for registered pharmacies preparing unlicensed medicines January 2014 1 The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians and registered pharmacies

More information

H. R. 6638. To amend chapter V of the Federal Food, Drug, and Cosmetic Act to enhance the requirements for pharmacies that compound drug products.

H. R. 6638. To amend chapter V of the Federal Food, Drug, and Cosmetic Act to enhance the requirements for pharmacies that compound drug products. I 1TH CONGRESS D SESSION H. R. To amend chapter V of the Federal Food, Drug, and Cosmetic Act to enhance the requirements for pharmacies that compound drug products. IN THE HOUSE OF REPRESENTATIVES DECEMBER,

More information

From the Text. Definitions. Definitions. Definitions. Definitions. RSPT 2217 Basic Concepts & Principles. RSPT 2217-01 Basic Concepts

From the Text. Definitions. Definitions. Definitions. Definitions. RSPT 2217 Basic Concepts & Principles. RSPT 2217-01 Basic Concepts RSPT 2217 & Principles Gardenhire Chapter 1; p. 1-10 From the Text Key Terms and page 2 Orphan Drugs Table 1-1; page 6 Abbreviations Table 1-2; page 8 Aerosolized Agents Table 1-3; page 9 Drug: Pharmacology:

More information

CHAPTER 131. SENATE BILL No. 33

CHAPTER 131. SENATE BILL No. 33 CHAPTER 131 SENATE BILL No. 33 AN ACT concerning the state board of pharmacy; pharmacy technicians; terms and membership of the state board of pharmacy; fingerprinting and criminal history record checks;

More information

Educational Outcomes for Pharmacy Technician Programs in Canada

Educational Outcomes for Pharmacy Technician Programs in Canada Canadian Pharmacy Technician Educators Association (CPTEA) Educational Outcomes for Pharmacy Technician Programs in Canada March 2007 Educational Outcomes for Pharmacy Technician Page 1 of 14 Framework

More information

Amgen GLOBAL CORPORATE COMPLIANCE POLICY

Amgen GLOBAL CORPORATE COMPLIANCE POLICY 1. Scope Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers and temporary staff worldwide ( Covered Persons ). Consultants, contract workers,

More information

STANDARDS AND GUIDELINES TITLE: CIRCULATION DATE: March June 2013 REVISED: June 2013 APPROVAL DATE: July 29, 2013

STANDARDS AND GUIDELINES TITLE: CIRCULATION DATE: March June 2013 REVISED: June 2013 APPROVAL DATE: July 29, 2013 College of Homeopaths of Ontario 163 Queen Street East, 4 th Floor, Toronto, Ontario, M5A 1S1 TEL 416-862-4780 OR 1-844-862-4780 FAX 416-874-4077 www.collegeofhomeopaths.on.ca STANDARDS AND GUIDELINES

More information

A safe return and reuse protocol in the community pharmacy setting may include, but is not limited to, the following elements:

A safe return and reuse protocol in the community pharmacy setting may include, but is not limited to, the following elements: National Association of Boards of Pharmacy Position Statement on the Return and Reuse of Prescription Medications in the Community Pharmacy Setting July 2009 The National Association of Boards of Pharmacy

More information

Jay Campbell Executive Director North Carolina Board of Pharmacy

Jay Campbell Executive Director North Carolina Board of Pharmacy Jay Campbell Executive Director North Carolina Board of Pharmacy I have no relationships with commercial interests related to the content of my presentation. Assessment Questions TRUE or FALSE: The federal

More information

Drug Supply Chain Security Act (Title II of the Drug Quality and Security Act) Overview and Implementation

Drug Supply Chain Security Act (Title II of the Drug Quality and Security Act) Overview and Implementation Drug Supply Chain Security Act (Title II of the Drug Quality and Security Act) Overview and Implementation Connie Jung, RPh, PhD U.S. Food and Drug Administration NACDS Total Store Expo August 24, 2014

More information

Revised checklist for BA/BE NOC effective from 01 st February 2014 (Draft for comments before 25 Jan 14)

Revised checklist for BA/BE NOC effective from 01 st February 2014 (Draft for comments before 25 Jan 14) Revised checklist for BA/BE NOC effective from 01 st February 2014 (Draft for comments before 25 Jan 14) Documents to be submitted for grant of permission to conduct BA/BE studies in Human Subjects/Patients

More information

Guide to Advertising Compliance

Guide to Advertising Compliance Guide to Advertising Compliance SUR-G0025-2 13 JUNE 2014 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. 1 INTRODUCTION This document gives

More information

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal

More information

- 1 - First Time Pharmacy Managers (Revised 02/02/2011)

- 1 - First Time Pharmacy Managers (Revised 02/02/2011) State of Connecticut Department of Consumer Protection Commission of Pharmacy 165 Capitol Avenue, Room 147 Hartford, CT 06106 - Telephone: 860-713-6070 ALL FIRST-TIME PHARMACY MANAGERS ARE REQUIRED TO

More information

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof; DIRECTIVE 65/65/EEC Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 of

More information

Introduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs

Introduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs Introduction to Drug Naming Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs What s in a Name? International Nonproprietary Names (INN) Sponsored by World Health

More information

Controlled Substance Policy and Procedures NORTHERN ILLINOIS UNIVERSITY OFFICE OF RESEARCH COMPLIANCE AND INTEGRITY

Controlled Substance Policy and Procedures NORTHERN ILLINOIS UNIVERSITY OFFICE OF RESEARCH COMPLIANCE AND INTEGRITY 2015 Controlled Substance Policy and Procedures NORTHERN ILLINOIS UNIVERSITY OFFICE OF RESEARCH COMPLIANCE AND INTEGRITY Contents A. Controlled Substance Policy... 4 1. Background, Purpose, and Scope...

More information

Board of Pharmacy Legislative Update Allison M. Dudley, J.D. Executive Director Board of Pharmacy. Disclosure. Objectives 9/9/2015

Board of Pharmacy Legislative Update Allison M. Dudley, J.D. Executive Director Board of Pharmacy. Disclosure. Objectives 9/9/2015 Board of Pharmacy Legislative Update Allison M. Dudley, J.D. Executive Director Board of Pharmacy Disclosure I have nothing to disclose and further, I was not paid an honorarium or travel reimbursement

More information

Rules of Department of Insurance, Financial Institutions and Professional Registration Division 2220 State Board of Pharmacy Chapter 2 General Rules

Rules of Department of Insurance, Financial Institutions and Professional Registration Division 2220 State Board of Pharmacy Chapter 2 General Rules Rules of Department of Insurance, Financial Institutions and Professional Registration Chapter 2 General Rules Title Page 20 CSR 2220-2.005 Definitions...3 20 CSR 2220-2.010 Pharmacy Standards of Operation...3

More information

LEGISLATURE OF THE STATE OF IDAHO Sixty-third Legislature First Regular Session - 2015 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO.

LEGISLATURE OF THE STATE OF IDAHO Sixty-third Legislature First Regular Session - 2015 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. LEGISLATURE OF THE STATE OF IDAHO Sixty-third Legislature First Regular Session - IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. BY HEALTH AND WELFARE COMMITTEE 0 AN ACT RELATING TO PHARMACIES; AMENDING

More information

ExCPT Certified Pharmacy Technician (CPhT) Detailed Test Plan* 100 scored items, 20 pretest items Exam time: 2 hours 10 minutes

ExCPT Certified Pharmacy Technician (CPhT) Detailed Test Plan* 100 scored items, 20 pretest items Exam time: 2 hours 10 minutes ExCPT Certified Pharmacy Technician (CPhT) Detailed Test Plan* 100 scored items, 20 pretest items Exam time: 2 hours 10 minutes # scored items 1. Regulations and Pharmacy Duties 35 A. Overview of technician

More information

DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE PHARMACY PROGRAM FOR UTILIZATION OF UNUSED PRESCRIPTION DRUGS

DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE PHARMACY PROGRAM FOR UTILIZATION OF UNUSED PRESCRIPTION DRUGS DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE PHARMACY PROGRAM FOR UTILIZATION OF UNUSED PRESCRIPTION DRUGS (By authority conferred on the director of the department of licensing and

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products For questions on the content of the guidance,

More information

RULES OF THE TENNESSEE BOARD OF NURSING CHAPTER 1000-04 ADVANCED PRACTICE NURSES AND CERTIFICATES OF FITNESS TO PRESCRIBE TABLE OF CONTENTS

RULES OF THE TENNESSEE BOARD OF NURSING CHAPTER 1000-04 ADVANCED PRACTICE NURSES AND CERTIFICATES OF FITNESS TO PRESCRIBE TABLE OF CONTENTS RULES OF THE TENNESSEE BOARD OF NURSING R 1000-04 ADVANCED PRACTICE NURSES AND CERTIFICATES TABLE OF CONTENTS 1000-04-.01 Purpose and Scope 1000-04-.07 Processing of Applications 1000-04-.02 Definitions

More information

AMBERLITE IRP69 Pharmaceutical Grade Cation Exchange Resin (Sodium Polystyrene Sulfonate USP)

AMBERLITE IRP69 Pharmaceutical Grade Cation Exchange Resin (Sodium Polystyrene Sulfonate USP) AMBERLITE IRP69 Pharmaceutical Grade Cation Exchange Resin (Sodium Polystyrene Sulfonate USP) Description AMBERLITE IRP69 [1] resin is an insoluble, strongly acidic, sodium form cation exchange resin supplied

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

IMP management at site. Dmitry Semenyuta

IMP management at site. Dmitry Semenyuta IMP management at site Dmitry Semenyuta TOP 5 FDA inspections finding 1999-2009 Center of Drug Evaluation and Research (CDER) Failure to follow the protocol Failure to keep adequate and accurate records

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Submitting Debarment Certification Statements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document

More information

Michael D. Bullek BSP Rph. Commissioner, New Hampshire Board of Pharmacy

Michael D. Bullek BSP Rph. Commissioner, New Hampshire Board of Pharmacy Michael D. Bullek BSP Rph. Commissioner, New Hampshire Board of Pharmacy Legislative changes PDMP program changes 503B outsourcing facilities Rules changes Ph800 review Ph300 Ph400 Ph700 Current issues

More information

Annex 9 Guide to good storage practices for pharmaceuticals 1

Annex 9 Guide to good storage practices for pharmaceuticals 1 World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilities

More information

Minimum Performance and Service Criteria for Medicare Part D

Minimum Performance and Service Criteria for Medicare Part D Minimum Performance and Service Criteria for Medicare Part D 1. Terms and Conditions. In addition to the other terms and conditions of the Pharmacy Participation Agreement ( Agreement ), the following

More information

PRIVACY NOTICE. In certain situations, we may also disclose patient information to another provider or health plan for their health care operations.

PRIVACY NOTICE. In certain situations, we may also disclose patient information to another provider or health plan for their health care operations. 1 PRIVACY NOTICE THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY. This Privacy Notice is being

More information

DRUG REPOSITORY PROGRAM

DRUG REPOSITORY PROGRAM OHIO STATE BOARD OF PHARMACY 77 S. High Street, Room 1702; Columbus, OH 43215-6126 Tel: 614-466-4143 Email: exec@bop.state.oh.us DRUG REPOSITORY PROGRAM ORC - Ohio Revised Code OAC - Ohio Administrative

More information

DIVISION 25 CERTIFIED OREGON PHARMACY TECHNICIANS AND PHARMACY TECHNICIANS

DIVISION 25 CERTIFIED OREGON PHARMACY TECHNICIANS AND PHARMACY TECHNICIANS 855-025-0001 DIVISION 25 CERTIFIED OREGON PHARMACY TECHNICIANS AND PHARMACY TECHNICIANS Purpose and Scope Transition from Registration of Technician to Licensure of Technician The purpose of the Pharmacy

More information

ANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS

ANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS ANASTROZOLE 1 MG FILM-COATED TABLETS (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics

More information

GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS

GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS Prepared by Ad Hoc Committee on Nuclear Pharmacy Technicians Nuclear Pharmacy Section Academy of Pharmacy Practice and Management American Pharmaceutical

More information

Pursuant to the authority vested in the Commissioner of Health by Article 33 of the

Pursuant to the authority vested in the Commissioner of Health by Article 33 of the Electronic Prescriptions and Records for Hypodermic Needles and Hypodermic Syringes Effective date: 10/9/13 Pursuant to the authority vested in the Commissioner of Health by Article 33 of the Public Health

More information